Research Topics
| Marc A RiedlSummaryAffiliation: University of California Country: USA Publications
| Collaborators |
Detail Information
Publications
Efficacy and safety of recombinant C1 inhibitor for the treatment of hereditary angioedema attacks: a North American open-label studyMarc A Riedl
University of California Los Angeles, David Geffen School of Medicine, Los Angeles, California 90095 1680, USA
Ann Allergy Asthma Immunol 110:295-9. 2013..The efficacy of recombinant human C1 inhibitor (rhC1INH) for the treatment of patients with acute hereditary angioedema (HAE) attacks has been demonstrated in 2 randomized, double-blind, placebo-controlled studies...- Hereditary angioedema therapies in the United States: movement toward an international treatment consensusMarc Riedl
Section of Clinical Immunology and Allergy, Department of Medicine, UCLA David Geffen School of Medicine, Los Angeles, CA 90095 1680, USA
Clin Ther 34:623-30. 2012..Pharmacologic developments in HAE treatment have culminated in the recent introduction of 4 new HAE-specific therapies in the United States... - Nanofiltered C1 esterase inhibitor (human) for the treatment of acute attacks of hereditary angioedema: an open-label trialMarc A Riedl
Department of Clinical Immunology and Allergy, David Geffen School of Medicine, University of California, Los Angeles, California 90095, USA
Ann Allergy Asthma Immunol 108:49-53. 2012..Hereditary angioedema (HAE) is a rare disease caused by C1INH gene mutations, which leads to a deficiency or dysfunction of C1 inhibitor (C1 INH), resulting in recurrent episodes of severe and potentially life-threatening edema... - Current medical management of hereditary angioedema: results from a large survey of US physiciansMarc Riedl
Section of Clinical Immunology and Allergy, Department of Medicine, University of California, Los Angeles, David Geffen School of Medicine, 90095, USA
Ann Allergy Asthma Immunol 106:316-322.e4. 2011..There are no known surveys of US physicians' knowledge and experience regarding the epidemiology, diagnosis, and management of HAE... - Update on the acute treatment of hereditary angioedemaMarc A Riedl
Department of Medicine, University of California Los Angeles, 90095, USA
Allergy Asthma Proc 32:11-6. 2011..Clinicians should consider a number of patient- and medication-specific factors when designing individualized treatment plans for HAE patients... - Response time for ecallantide treatment of acute hereditary angioedema attacksMarc Riedl
University of California at Los Angeles, David Geffen School of Medicine, Los Angeles, California 90095 1680, USA
Ann Allergy Asthma Immunol 105:430-436.e2. 2010..Ecallantide is a novel plasma kallikrein inhibitor developed for the treatment of acute HAE attacks... 
Oral sulforaphane increases Phase II antioxidant enzymes in the human upper airwayMarc A Riedl
The Hart and Louis Laboratory, Clinical Immunology and Allergy, Department of Medicine, UCLA David Geffen School of Medicine, 10833 Le Conte Avenue, Los Angeles, CA 90095, USA
Clin Immunol 130:244-51. 2009..Endogenous Phase II enzymes abrogate oxidative stress through the scavenging of reactive oxygen species and metabolism of reactive chemicals...
The effect of air pollution on asthma and allergyMarc A Riedl
Division of Pulmonary and Critical Care Medicine, UCLA David Geffen School of Medicine, Los Angeles, CA 90095, USA
Curr Allergy Asthma Rep 8:139-46. 2008....- Importance of oxidative stress in the pathogenesis and treatment of asthmaMarc A Riedl
Section of Clinical Immunology and Allergy, Division of Pulmonary and Critical Care Medicine, UCLA David Geffen School of Medicine, Los Angeles, California 90095, USA
Curr Opin Allergy Clin Immunol 8:49-56. 2008..The purpose of the current review is to summarize recent evidence demonstrating the important role of oxidative stress in asthma pathogenesis. The therapeutic implications of these findings will be presented... - Initial high-dose nasal allergen exposure prevents allergic sensitization to a neoantigenMarc A Riedl
Hart and Louis Lyon Laboratory, Division of Clinical Immunology and Allergy, Department of Medicine, David Geffen School of Medicine, University of California, Los Angeles, 90095, USA
J Immunol 174:7440-5. 2005..Whether this immune response represents durable allergic tolerance is not yet known. Studies investigating the molecular mechanisms of this non-IgE response may be useful in developing therapy to prevent allergic sensitization... - Adverse drug reactions: types and treatment optionsMarc A Riedl
University of California, Los Angeles, David Geffen School of Medicine, Los Angeles, California 90095, USA
Am Fam Physician 68:1781-90. 2003..Reactions to radiocontrast media can be limited by pretreatment with prednisone, diphenhydramine, and either ephedrine or a histamine H2-receptor antagonist... - Novel antioxidant approaches to the treatment of upper airway inflammationMelinda Braskett
Department of Medicine, University of California, Los Angeles, USA
Curr Opin Allergy Clin Immunol 10:34-41. 2010..This review summarizes recent investigations of novel antioxidant agents for upper airway inflammation, with selected studies focused on lower airway disease as additional candidate therapeutics...